# XRCC1

Source: https://onco.cc/targets/xrcc1/  
OnCo record `xrcc1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

XRCC1 (DNA repair protein XRCC1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Non-small-cell lung cancer.

## Summary

Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes. Negatively regulates ADP-ribosyltransferase activity of PARP1 during base-excision repair in order to prevent excessive PARP1 activity. Recognises and binds poly-ADP-ribose chains: specifically binds auto-poly-ADP-ribosylated PARP1, limiting its activity.

CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Docetaxel, Gemcitabine, Carboplatin and Vinorelbine and others. Open Targets scores its association with cancer at 0.50 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.78).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: X-ray repair cross complementing 1; DNA repair protein XRCC1
- Tags: cancer-genes-wave
- Symbol: XRCC1
- Class: other
- Biology: Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes. Negatively regulates ADP-ribosyltransferase activity of PARP1 during base-excision repair in order to prevent excessive PARP1 activity. Recognises and binds poly-ADP-ribose chains: specifically binds auto-poly-ADP-ribosylated PARP1, limiting its activity. Location: Nucleus; Chromosome (UniProt). Locus 19q13.31 (HGNC).
- Where found: Cervical cancer: CIViC evidence names this disease; Non-small-cell lung cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 5 therapies; CIViC holds 3 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:12828: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12828
- UniProt P18887: https://www.uniprot.org/uniprotkb/P18887/entry
- NCBI Gene 7515: https://www.ncbi.nlm.nih.gov/gene/7515
- Ensembl ENSG00000073050: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000073050

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- pathways: [Base excision repair, PARP & alkylation damage](https://onco.cc/pathways/base-excision-repair-parp/)

---
JSON: https://onco.cc/api/v1/entities/xrcc1.json